drugset / Trial / NCT07052383
Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
Phase 1
Recruiting
15 enrolled
Tcelltech Inc.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a open-Label, dose-escalation study to evaluate the safety, tolerability and antitumor activity of DIT309 in subjects with advanced bone and soft tissue sarcomas.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.
Timeline
- Start
- 2025-11-06
- Primary completion
- 2027-10-10
- Completion
- 2027-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DIT309 | Unknown | — | Intravenous |